Clinical Research on Advanced Warning Factors Of Respiratory Injury in Dermatomyositis
CRAWFORD
1 other identifier
observational
1,000
1 country
1
Brief Summary
Dermatomyositis (DM) is a highly heterogeneous autoimmune disease characterized by rash and myasthenia. Beside these, respiratory involvement is one of the common complications of DM. Interstitial lung disease (ILD) occur in approximately 90% of patients with DM, part of them may manifest rapidly progressive-interstitial lung disease (rp-ILD), which progresses into respiratory failure that is difficult to correct and leads to death. Early identification of rp-ILD high risk group is of great significance to improve the prognosis of patients and to conduct following clinical studies. A simple, easy, convenient and reliable diagnostic tool has not yet acquired till now.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2020
CompletedFirst Submitted
Initial submission to the registry
February 7, 2021
CompletedFirst Posted
Study publicly available on registry
February 10, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedJuly 1, 2021
June 1, 2021
2.6 years
February 7, 2021
June 29, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
death
death caused by dermatomyositis and its related complications
within 12 months after disease oneset
Eligibility Criteria
Recruit inpatients from department of rheumatology and immunology of eighteen tertiary hospitals in Jiangsu province
You may qualify if:
- adult patients meet the diagnostic criteria for dermatomyositis of Bohan and Peter
You may not qualify if:
- complicated with other connective tissue diseases
- complicated with cardiovascular and respiratory disease caused by other reasons
- interstitial lung disease caused by environment and drugs
- patients with key research missing data or without informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, 210029, China
Related Publications (1)
Wang L, Lv C, You H, Xu L, Yuan F, Li J, Wu M, Zhou S, Da Z, Qian J, Wei H, Yan W, Zhou L, Wang Y, Yin S, Zhou D, Wu J, Lu Y, Su D, Liu Z, Liu L, Ma L, Xu X, Zang Y, Liu H, Ren T, Liu J, Wang F, Zhang M, Tan W. Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model. Front Immunol. 2024 Feb 1;15:1286973. doi: 10.3389/fimmu.2024.1286973. eCollection 2024.
PMID: 38361940DERIVED
Biospecimen
peripheral blood mononuclear cell, serum or plasma, muscle and lung biopsy specimen
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 12 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief Physician
Study Record Dates
First Submitted
February 7, 2021
First Posted
February 10, 2021
Study Start
June 1, 2020
Primary Completion
December 31, 2022
Study Completion
December 31, 2022
Last Updated
July 1, 2021
Record last verified: 2021-06